Dianthus Therapeutics
Dianthus Therapeutics Inc is an American clinical-stage biotechnology company developing targeted complement therapies for severe autoimmune diseases. The company engineers monoclonal antibodies that selectively inhibit active complement pathway proteins, including lead candidate DNTH103. Main revenue drivers currently comprise investment capital, milestone grants, and development licensing collaborations as clinical pipelines advance. Dianthus Therapeutics targets clinical research centers, rheumatology specialists, and patients suffering from rare autoimmune neuromuscular and hematologic disorders. The company holds a specialized market position in next-generation complement biology drug design. Headquartered in Waltham, Massachusetts, Dianthus Therapeutics Inc is listed on the Nasdaq Stock Market.
7 of the funds FundTelligence covers report a position in Dianthus Therapeutics.
- Legal name
- Dianthus Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
- Exposure themes
- Autoimmune diseases, Treatment, Women's Health
Funds holding Dianthus Therapeutics
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.97 % (full portfolio disclosed, September 2026)
- DNB Bioteknologi — DNB · 1.26 % (full portfolio disclosed, September 2026)
- DNB Fund Women's Health — DNB · 1.18 % (full portfolio disclosed, August 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.46 % (full portfolio disclosed, October 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.15 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.0 % (full portfolio disclosed, September 2026)